Filter News

Vermillion Sets Third Quarter 2014 Conference Call for Thursday, November 13, 2014

Published: Oct 31, 2014

AUSTIN, Texas, Oct. 30, 2014 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Thursday, November 13, 2014, at 4:30 p.m. Eastern time to discuss results for the third quarter ended September 30, 2014. Financial results will be issued in a press release prior to the call.

Vermillion's Chairman, President and CEO James LaFrance will host the call, followed by a question and answer period.

Date: Thursday, November 13, 2014
Time: 4:30 p.m. Eastern time (3:30 p.m. Central time)
Dial-in number: 1-888-264-8943
International dial-in number: 1-913-981-5540
Conference ID: 2787200
Webcast:  http://edge.media-server.com/m/p/gs4hfyiu/lan/en

The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Vermillion Inc. at 512-519-0400.

A replay of the call will be available approximately three hours after the call until November 27, 2014.

Toll-free replay number: 1-877-870-5176
International replay number: 1-858-384-5517
Replay ID: 2787200

About Vermillion

Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.

Investor Relations Contact:
Eric Schoen
VP, Finance and Chief Accounting Officer
Tel 1-512-519-0424
eschoen@vermillion.com

SOURCE Vermillion, Inc.

Help employers find you! Check out all the jobs and post your resume.

Back to news